Search DubaiPRNetwork.com

Dubai and UAE

Saturday, February 8, 2020/ Editor

Home >> Healthcare and Fitness

NYU Abu Dhabi Researchers Design Proteins That Can Be Utilized to Combat Alzheimer's Disease

NYU Abu Dhabi Researchers Design Proteins That Can Be Utilized to Combat Alzheimer's Disease

Home >> Healthcare and Fitness
Protein-based therapeutics prevent protein aggregation associated with Alzheimer’s and other neurodegenerative diseases
 
Fast facts
● Alzheimer’s disease, an irreversible and progressive brain disorder, is the most common cause of dementia. 
● A hallmark of Alzheimer’s disease is the aggregation of the amyloid-β (Aβ) protein in a process that is toxic to the brain’s neurons. As neurons die, this slowly destroys memory and cognitive function. 
● NYUAD researchers have developed small proteins called cell-penetrating peptides (CPPs) that prevent the aggregation of the Aβ protein. 
● The paper Designed cell-penetrating peptide inhibitors of amyloid-beta aggregation and cytotoxicity has been published in Cell Reports Physical Science.
 
Abu Dhabi, UAE, February 7, 2020: A team of researchers, led by NYU Abu Dhabi Assistant Professor of Biology Mazin Magzoub, has developed small proteins called cell-penetrating peptides (CPPs) that prevent the aggregation of the amyloid-β (Aβ) protein associated with Alzheimer’s disease. 
 
There is a growing interest in the use of proteins to develop treatments because they are biocompatible, biodegradable, and can selectively bind to specific targets, which reduces the potential for toxicity. Other pharmaceutically-desirable properties of proteins include greater chemical diversity than other biological molecule classes, and ease and low cost of production. However, a significant obstacle to the successful application of most proteins as therapeutics is their poor delivery to target organs and cells. 
 
In a new study, the Magzoub lab in collaboration with Professor and NYU President Andrew Hamilton’s lab at NYU New York and Professor Astrid Gräslund’s lab at Stockholm University, report that they have engineered CPPs that effectively prevent the aggregation of Aβ. CPPs are a special class of proteins that have the ability to reach all organs, including the brain, and to efficiently enter cells within these organs. Thus, the designed CPPs combine the attractive properties of proteins with potent therapeutic effects and highly efficient delivery to target cells.
 
A broad range of neurodegenerative diseases, including Huntington’s, Parkinson’s, and Alzheimer’s, are caused by the misfolding of disease-specific proteins. Once misfolded, these proteins build up in a process that damages neurons. Previously, the team showed that a naturally-derived CPP was able to protect against abnormal and harmful forms of the protein associated with prion diseases, a class of neurodegenerative disorders that include mad cow disease in cattle and Creutzfeldt-Jakob disease (CJD) in humans. Here, Magzoub and his collaborators extended this approach and specifically applied it to Alzheimer’s disease-causing Aβ malformation. 
 
In the paper titled Designed cell-penetrating peptide inhibitors of amyloid-beta aggregation and cytotoxicity, the researchers present the process of designing the Aβ inhibitor CPPs. Using a range of techniques, they then extensively characterized the interactions of the designed CPPs with Aβ. Specifically, they used established aggregation and cell viability assays to determine the effects of the designed CPPs on the aggregation and associated neurotoxicity of Aβ. Simultaneously, they probed the cellular uptake and intracellular distribution of Aβ in the presence of the CPPs with confocal fluorescence microscopy. Finally, they used a combination of experiments and computer simulations to shed light on the mechanism of binding of the CPPs to Aβ. The results show that the designed CPPs stabilize the Aβ protein in a non-aggregated, non-abnormal state, and inhibit Aβ induced neurotoxicity.
 
The CPPs designed in this study effectively target Aβ outside and inside neurons, thereby protecting them against the damage caused by Aβ aggregation. “The designed CPPs represent a novel potential treatment strategy for Alzheimer’s disease,” said Magzoub. “These findings also reveal a general underlying principle for inhibition of pathogenic protein aggregation that will facilitate the design of even more potent CPP-based therapeutics for various neurodegenerative diseases.”

 

Share


Previous in Healthcare and Fitness

Next in Healthcare and Fitness


Home >> Healthcare and Fitness Section

Latest Press Release

Mohammed Bin Rashid Innovation Fund Launches a New Chapter to Strengthen Government Innovation

RTA Completes Traffic Upgrades to Improve Connectivity Between Sheikh Zayed Road and Al Khail Road v ...

Dubai Municipality Announces Registration Opening for the Second Edition of the Food Systems Excelle ...

Emirates Aviation University marks 35 years of supporting the local and global aviation ecosystem

Emirates layers on retrofitted aircraft with latest product, including Premium Economy to more citie ...

Music, Maps, and Stories at the Mohammed Bin Rashid Library in July

New SHEGLAM Daydreamer Mini Palette Turns Pocket-Sized into Power Pigment

GEMS Education launches GEMS School Management (GSM) to deliver world-class schools globally; in adv ...

Dubai Airshow 2025 unveils new features as registration opens, promising unmatched experiences on an ...

Passenger Growth Hits 5% in May

João Almeida: Racing for Glory and Riding for the Team

May Air Cargo Demand Up 2.2% Despite Trade Disruptions

Return to Ritual: Celebrate Self-Care Month with BUFARMA Skincare

Dubai Government Human Resources Department organises 2nd Human Resources Forum of 2025 to discuss e ...

Dubai Customs and Dubai Police: A strategic partnership to protect the homeland and to promote stabi ...

Rediscover family shopping days: REDTAG opens its doors in Al Ain

Dubai Culture Launches Open Call for 14th Sikka Art & Design Festival

Summer Restaurant Week Returns This DSS with Over 65 Exclusive Dining Deals Across Dubai

Julien Calloud Appointed CEO of SAVOYE to Lead a New Era of Performance and Innovation

Zoho Powers Up CRM for Everyone Platform with AI to Elevate Customer Experience